Kornimate/medical-research-clean huggingface dataset:
effect of active cycle breathing technique along with incentive spirometer on covid19 patient

Conditions: Corona Virus Infection

Summary: this study will be conducted to investigate the effect of active cycle breathing technique and incentive spirometer on covid19 patient

severe acute respiratory syndrome coronavirus 2 (sars-cov-2) is a new coronavirus that emerged in 2019 and causes coronavirus disease 2019 (covid-19).individuals with covid-19 can present with an influenza-like illness and respiratory tract infection demonstrating fever (89%),cough (68%), fatigue (38%), sputum production (34%) and/or shortness of breath (19%). the spectrum of disease severity ranges from asymptomatic infection or mild upper respiratory tract illness through to severe viral pneumonia with respiratory failure and/or death. current reports estimate that 80% of cases are asymptomatic or mild; 15% of cases are severe (infection requiring oxygen); and 5% are critical, requiring ventilation and life support. based on emerging data, individuals at the highest risk of developing severe covid-19 disease requiring hospitalization and/or icu support are those who are older, male, have at least one co-existing comorbidity, elevated d-dimer levels, and/or lymphocytopenia. active cycle breathing techniques (acbt) is a cycle of techniques consisting of breathing control, lower thoracic expansion exercises and the forced expiration technique modifiable to individual patients. it assists bronchial clearance by enhancing mucociliary clearance whilst reducing adverse effects such as hypoxemia or increased airflow obstruction. incentive spirometry (is) is a type of deep breathing exercise that is widely used for lung expansion and the prevention of pulmonary complications in children, adults, and the elderly. is is used to encourage the patient to inhale to lung capacity through maximal inspiration aided with visual feedback. these maneuvers increase transpulmonary pressure and therefore increase chest-wall volume.one hundred patients will be allocated randomly to two groups; one group will receive active cycle breathing with an incentive spirometer and the other will receive active cycle breathing

Eligibility criteria:
inclusion criteria: * ages from 45-75 years old * covid-19 patients with spo2 \> 85 * oxygen face mask or a reservoir mask exclusion criteria: * mechanically ventilated, * cancer, * chronic respiratory disease (defined as asthma or chronic obstructive pulmonary disease), * end-stage renal disease, * liver disease (defined as compensated/decompensated liver cirrhosis), * chronic neurological disease (defined as previous neurological disease), * chronic cardiovascular disease, * active smoker

Keywords: active cycle breathing incentive spirometer covid19
evaluating xperience™ advanced surgical irrigation

Conditions: Hip Osteoarthritis; Hip Arthritis; Knee Osteoarthritis; Knee Arthritis

Summary: a prospective, multi-center, double-arm, parallel, interventional, randomized, controlled clinical trial to assess the rate of periprosthetic joint infection (pji) in patients undergoing primary total knee arthroplasty (tka), total hip arthroplasty (tha) or hip resurfacing (hr) with xperience™ (xp) advanced surgical irrigation versus dilute betadine (db).


Eligibility criteria:
inclusion criteria: 1. male and female patients aged 18 years or older 2. diagnosis of osteoarthritis, inflammatory arthritis, osteonecrosis, or post-traumatic arthritis to the affected joint. 3. primary tka, tha, and hr 4. subjects receiving both cemented or uncemented orthopaedic implants 5. willing and able to sign written consent, follow study protocol and attend follow-up exclusion criteria: 1. inability or refusal to sign informed consent form 2. non-english or french speaking, and no licensed translator, family member or substitute decision maker available. 3. prior arthroplasty procedure to the affected joint 4. procedures involving solid ha implants 5. oncologic diagnosis to the affected joint. 6. non-tka, tha or hr prosthesis (i.e., hemiarthroplasty, unicompartmental arthroplasty etc.) 7. allergy to any of the components of xp advanced surgical irrigation 8. allergy to iodine 9. presence of concurrent active infection, primary immunodeficiency, history of uncontrolled hiv (cd4 count \<200 cells/ul), treatment with immunomodulatory medications for malignancy or autoimmune disease (with exception to inflammatory arthritis), chronic glucocorticosteroid use (≥20 mg of prednisone daily for at least 1 month with another cause of immunosuppression), and solid organ and/or bone marrow transplantation. 10. history of septic arthritis to the affected joint within two years of surgery(1). 11. history of steroid injection to the affected joint within the three months preceding surgery. 12. simultaneous bilateral total joint arthroplasty
compassionate use study of pergolide in patients with parkinson's disease

Conditions: Parkinson Disease

Summary: this compassionate use study is designed to monitor safety in patients who have been doing well on pergolide therapy, wish to continue treatment, and have not been able to tolerate alternative treatments.


Eligibility criteria:
inclusion criteria: * diagnosed with parkinson's disease and treated successfully with pergolide in the recent past * attempt to taper off pergolide was unsuccessful and patient was unable to change to other forms of therapy for parkinson's disease * no evidence of cardiovalvular disease by echocardiogram conducted within 60 days prior exclusion criteria: * history or current diagnosis of cardiac valvulopathy * inability to undergo echocardiograms every 6 months while receiving pergolide * hypersensitivity to pergolide or other ergot derivatives

Keywords: parkinson's disease antiparkinsonian compassionate use
characteristics of autism spectrum disorder in minors with anorexia nervosa in remission

Conditions: Anorexia Nervosa; Autism Spectrum Disorder

Summary: with this investigation, researchers wil look for a link between the appearance of anorexia nervosa and autism spectrum disorders in minors. previous studies made clear already that patients with anorexia nervosa show elevated characteristics of autism spectrum disorder, when being meassured in adults and in patients in the acute fase of their anorexia nervosa. the purpose of this invenstigation is to see if their is also an elevated incidence of characteristics of autism spectrum disorder in minors with anorexia nervosa in remission.

34 patients who are still minors and were previously treated in the child and adolescent psychiatry department (paika) of the university hospital in brussels, will be contacted to ask if they would volunteer in this investigation. if the minors and their parents give their permission, they will be asked to fill in multiple questionnaires, measuring the current symptoms of anorexia nervosa, characteristics of autism spectrum disorder and global functioning of the minors. the questionnaires will be send and returned by post.

Eligibility criteria:
inclusion criteria: * patients speaking dutch * previously treated in uz brussel for anorexia nervosa * informed consent signed by children and parent(s) exclusion criteria: * patients and/or parents don't speak dutch * adults * no informed consent obtained
micro-ultrasound in cancer - active surveillance

Conditions: Prostate Cancer

Summary: this study will compare the two imaging modalities (mri and micro-ultrasound) during active surveillance of prostate cancer (pca). progression to clinically significant pca will be assessed by first taking micro-us targeted samples (while blinded to mri results), followed by mri targeted samples, finishing with 12 systematic biopsy cores. the primary goal is to compare microus to mri for the detection of ≥gg2 pca at confirmatory biopsy. this study will also collect blood samples from participants to be used for future biomarker studies.


Eligibility criteria:
inclusion criteria: * adult men with gleason grade group 1 prostate cancer managed by active surveillance who require a confirmatory prostate biopsy exclusion criteria: * men who cannot undergo a prostate mri * men who cannot undergo a prostate biopsy

Keywords: active surveillance micro-ultrasound
augmented reality treadmill training in patients with parkinson's disease

Conditions: Parkinson Disease; Fall

Summary: gait disorder is a disabling symptom in parkinson's disease (pd) affecting all patients during the course. three methods of treadmill training (tt) will be compared to assess additional augmented reality (ar), or additional dual task (dt). ar tt, dt tt, and tt alone applied over 3 weeks at each day will be compared for their impact on falls, walking, freezing and attention for 3 months in a double blinded randomized controlled trial during regular neurorehabilitation.


Eligibility criteria:
inclusion criteria: * informed consent as documented by signature * parkinson´s disease without dementia and hallucination * at least one fall within the past 3 months or postural instability * gait disorder * hoehn and yahr stages ii-iv * able to perform the treadmill therapy during a study exclusion criteria: * contraindications to treadmill therapy (e.g. hip fracture) * dementia as defined by an montreal cognitive assessment (moca) \< 20

Keywords: parkinson disease
in utero exposure to sars-cov-2 (covid-19) and cardiovascular and metabolic endpoints in early life

Conditions: In Utero SARS-CoV-2 Exposure

Summary: since its initial outbreak in late 2019, coronavirus disease 2019 (covid-19) caused by the novel coronavirus sars-cov-2 has ravaged the globe, causing illness characterized by inflammation and impaired oxygen levels. as a particularly vulnerable group, pregnant women have had a heightened prevalence and severity of infection. in this context, a new population of children has emerged who were exposed to maternal covid-19 in the womb. as maternal diseases during pregnancy may impact the health of offspring over the life course, health outcomes among these individuals must be urgently evaluated. in the current study, the investigators will leverage a perinatal biorepository comprised of pregnant women with and without covid-19 to delineate the metabolic and cardiovascular risk profiles of these offspring. this work stands to benefit the burgeoning population of children exposed to covid-19 in the womb and to deepen the mechanistic understanding of developmental origins of cardiometabolic disease with respect to maternal infections.


Eligibility criteria:
inclusion criteria: * mother with or without prenatal covid-19 who was enrolled in the mgh covid-19 perinatal biorepository and her child (9-24 months old) exclusion criteria: * child with any history of documented covid-19 * mother who received the covid-19 vaccine during pregnancy with her child * significant chronic illness in mother or child judged by the investigator to represent a contraindication to study participation

Keywords: metabolic disease cardiovascular disease
a study to evaluate the efficacy and safety of add-on therapy of wuling capsule in epilepsy patients with depression

Conditions: Epilepsy; Depression

Summary: the main purpose of this study is to determine the effects of add-on therapy of wuling capsule on depressive symptoms in patients with comorbidity of epilepsy and depression, to evaluate its influences on the frequency and severity of seizures, and to observe its effects on patients' sleeping condition, quality of life.

the phenomenon of epileptic patients who have psychiatric disorders is very common, of which the prevalence of depression is the highest and depression is also an independent risk factor affecting epileptic patients' quality of life. due to some social factors, non-typical clinical symptoms and limited therapeutic methods(tricyclic antidepressants, lithium chloride and 5-serotonin uptake inhibitors may all have risks of lowing threshold of seizures), epileptic patients with depression are usually not be recognized and treated properly. wuling capsule has been used in therapy of insomnia, nervous breakdowns and a previous small sample clinical trial revealed that it could improve mood disorders of epileptic patients and hadn't affected severity of seizures (not published). therefore a multi-center, randomized, double-blinded and placebo-controlled superiority clinical trial will be carried out to determine the effects of add-on therapy of wuling capsule on depressive symptoms in patients with epilepsy, to evaluate its influences on the frequency and severity of seizures, and to observe its effects on patients' sleeping condition, quality of life.

Eligibility criteria:
inclusion criteria: subjects for this study will meet the following criteria: 1. age greater than or equal to 18 years. 2. must be in accordance with the diagnostic criteria of epilepsy and have taken antiepileptic drugs regularly at least for 6 months, which will not be changed recently. the duration to the latest seizure must be longer than 24 hours. 3. score of a 17 item hamilton depression is greater than or equal to 17 and depressive symptoms have lasted for at least 2 weeks. 4. haven't taken any anti-anxiety, anti-depressant and anti-psychotic drugs in recent 2 weeks. 5. must sign the informed consent form. exclusion criteria: 1. now accepting or have accepted other drugs clinical trial in the last month. 2. history of serious psychiatric illness other than depression. 3. having suicide ideas or suicide behaviors. 4. progressive illness of central nervous system, such as degenerative disease or tumor. 5. history of serious cardiac or pulmonary disease, hepatic and renal dysfunction, and malignant tumors. 6. the value of alt or ast is higher than 1.5 times normal range, or the number of white blood cells is less than 2500/ul, or the number of neutrophil granulocyte is less than 1000/ul. 7. during pregnant or lactation period. 8. the person who is disabled or mentally disabled.

Keywords: wuling capsule epilepsy depression superiority clinical research
ocriplasmin for treatment for symptomatic vitreomacular adhesion including macular hole

Conditions: Vitreomacular Adhesion Including Macular Hole

Summary: the purpose of this study is to evaluate the treatment of symptomatic vitreomacular adhesion / (vmt) including macular hole with ocriplasmin.

the present study is designed to assess anatomical and functional outcomes following a single intravitreal injection of ocriplasmin 0.125mg in subjects with symptomatic vitreomacular adhesion (vma)/ (vmt) including macular hole.

Eligibility criteria:
inclusion criteria: * subjects 18 years of age or older and of either gender * presence of vitreomacular adhesion * best corrected visual acuity (bcva) of 20/32 or worse in study eye * bcva of 20/800 or better in the non-study eye exclusion criteria: * history or current evidence of proliferative retinopathy, exudative age-related macular degeneration (amd) or retinal vein occlusion in the study eye * any vitreous hemorrhage or any other vitreous opacification which precludes the visualization of the posterior pole by visual inspection or adequate assessment of the macula by spectral-domain optical coherence tomography (sd-oct) in the study eye * macular hole of \> 400 µm diameter in the study eye * presence of epiretinal membrane (erm) * aphakia in the study eye * high myopia (more than 8d) in study eye * history of rhegmatogenous retinal detachment in either eye * history of vitrectomy in the study eye * previous participation in this trial or prior administration of ocriplasmin in the study eye
detailed clinical, biochemical and genetic characterization in gonadotropin-releasing hormone (gnrh) deficiency disorders

Conditions: Idiopathic Hypogonadotropic Hypogonadism; Hypothalamic Amenorrhea

Summary: in this study, we will measure levels of reproductive hormones and metabolic markers in subjects with isolated gnrh deficiency disorders and compare them to healthy control populations. our goals are (1) to chart the range of hormonal and metabolic biomarkers in healthy subjects and those with reproductive disorders and (2) to correlate reproductive and metabolic phenotypes with genetic changes within patients with reproductive disorders and healthy controls.


Eligibility criteria:
inclusion criteria: * over the age of 18 for men * between the ages of 18 and 40 for women * for reproductive disorder population: current or previous diagnosis of idiopathic hypogonadotropic hypogonadism or hypothalamic amenorrhea exclusion criteria: * chronic disease (hypertension, high cholesterol, diabetes, asthma, etc) * polycystic ovarian syndrome for women * prescription medication use (other than allergy meds) for control populations * irregular menstrual cycles for healthy female control population (cycle length longer than 35 days or shorter than 25 days. cycle length varies by more than 5 days. less than 9 periods per year)
investigating stress-related mechanisms in the laboratory and real world in individuals with cannabis use disorder

Conditions: Cannabis Use Disorder

Summary: this research project proposes a novel approach to elucidate the biological adaptations associated with cannabis use disorder and to assess whether such adaptations are predictive of higher drug craving in response to both drug cues and stressors in both the laboratory and real-world, and higher relapse risk and drug use in the real world.

the intent of this study is to recruit 25 treatment-seeking individuals with cannabis use disorder (cud) and 25 light users (\<1 joint/week) to complete three guided imagery conditions (stress, cannabis, neutral) in inpatient research units. during the guided imagery, repeated measurements of subjective (i.e., craving, negative affect), neuroendocrine (i.e., cortisol), and physiological variables (i.e., heart rate variability \[hrv\]) will be collected. thereafter, individuals with cud will begin one-month of drug counseling treatment coupled with surveys delivered via smartphones daily in the morning, evening, and at four random times during the day.

Eligibility criteria:
inclusion criteria: * cannabis using men and women who: * 1. are fluent in english; * 2. are using cannabis at levels to match either of the two groups: a) light users: i. cannabis using levels of \< 1 joint/week ii. has never met dsm-5 criteria for cud or other substance use disorders. b) individuals with cannabis use disorder: i. meets criteria for cud based on the scid (≤ 2 symptoms in past year); ii. has a past-year cannabis use pattern of ≤3 times per week; iii.do not meet criteria for any other substance use disorders other than mild alcohol use disorder. * 3. provide a negative breathalyzer for alcohol and only positive for cannabis use at all appointments; * 4. can provide written informed consent. exclusion criteria: * 1. meets current or past dsm-5 criteria for axis i for major psychiatric disorders, other than depression or anxiety disorder; * 2. meets criteria for a current substance use disorder other than cannabis or mild alcohol use disorder; * 3. has any significant current medical conditions requiring medication, including neurological, renal, thyroid, cardiovascular, liver, endocrine, or immune conditions; * 4. reports current use of medications/drugs that interfere with hpa axis response, * 5. are women who are pregnant or lactating, are peri-/post-menopausal, or those with hysterectomies; * 6. report current use of psychotropic drugs other than antidepressants.
ngs assessment of congenitally deafned children and neonatal deafness screnning

Conditions: Congenital Deafness; Suspicion of Congenital Deafness

Summary: to assess the diagnostic value of ngs screnning in prelingually deafned children using a new designed chip, and to evaluate its interest in a the neonatal screening program for ddetecting congenitally deafned children.

the aim of the study is to evaluate the diagnostic value of a new panel of gene in ngs study in children presenting : 1. a congenitally deafness : it is a retrospective study in children aged 0 to 17 yrs with hearing thresholds over 40 db in the best ear using adapted audiometric assessment, 2. a suspicion of deafness in babies aged 0 to 6 months having an abnormal response after otoacoustic emissions and automated abr assessment. the main outcomes studied will be the finding of a pathogenic mutation (or several mutations).

Eligibility criteria:
inclusion criteria: * retropective study inclusion criteria: * age of onset of deafness between 0 and 17 years * with a hearing loss of one or two senses with, on the ear most affected, a hearing loss more than 40 db in mean audiometric loss in behavioural audiometry * availability of detailed information in appendix 1: history, history and course of disease, associated symptoms, otoscopy data, radiology, treatments and hearing aids implemented. * availability of dna samples stored in an existing collection. * consent to participate in the study (non-opposition) by the legal representative exclusion criteria: * exclusion criteria: * child with a known cause of observed deafness (meningitis, post-surgery or drug iatrogenic, trauma, infections, tumor) * family not willing to participate in the study prospective study inclusion criteria: * age of the child 0 to 6 months including corrected age having had on at least one of the two ears a lack of acoustic otoemissions and a lack of response in automated pea, and a threshold of pea at least on one ear at more than 40 db. * availability of detailed information in appendix 2: personal history, family history of deafness, associated symptoms, tympanometry, otoscopy data, neonatal deafness test data. * collection of the consent of the legal representative exclusion criteria: · family not willing to participate in the study

Keywords: deafness child
emotional and change-related attention in autism

Conditions: Autism Spectrum Disorders

Summary: several studies seem to indicate that emotional attention and change-related attention are impaired in asd. the goal of this study is to identify the relationships between those two types of automatic attention in visual and auditory modalities in subjects with asd compared to healthy controls and also, over the course of development (children, adults). in order to achieve this goal, the investigators will use complementary techniques (eeg and mri-based techniques (fmri, dti)).

autism spectrum disorders (asd) are characterized by major handicap in social interaction and in daily life adaptation. the orienting response towards potentially relevant events involves automatic attentional mechanisms that would be elicited mainly by two classes of biologically important stimulations: novel stimuli and emotional stimuli. the neural basis of emotional and change-related attention in asd will be explored by investigating brain reactivity in both visual and auditory modalities, during tasks mixing emotional and non emotional stimuli.

Eligibility criteria:
inclusion criteria: * no past history of central nervous system disorders * written consent * affiliated to the national health insurance * do not participate to another biomedical research * for asd group: children with autism spectrum disorder (dsm-v criteria) and adults with high-functioning autism * for healthy subjects: no past history of difficulties in early childhood for acquisition of walk, language or reading and no psychiatric disorders exclusion criteria: * abnormal corrected vision * abnormal audition * not stabilized psychoactive treatment or treatment that can modify electrogenesis * infectious or metabolic diseases * epilepsies * impossibility to participate to the whole study * for subjects participating to the mri recordings: mri counter-indications (pace-makers ...), claustrophobia or a positive pregnancy test

Keywords: autism spectrum disorders emotion attention event-related potential functional neuroimaging diffusion tensor imaging development